Quantcast
Last updated on April 16, 2014 at 8:06 EDT

Latest Folinic acid Stories

2012-09-18 06:29:34

BEDFORD, Ohio, Sept. 18, 2012 /PRNewswire/ -- Bedford Laboratories((TM)) today announced the expansion of its previous nationwide voluntary recall for Leucovorin Calcium Liquid Injection: Product Description NDC Package Size Lot#/Expiration Date First Ship Date Last Ship Date ---...

2012-09-05 02:33:12

WEST CONSHOHOCKEN, Pa., Sept. 5, 2012 /PRNewswire/ -- BTG International Inc., the specialist healthcare company, today announces that the Centers for Medicare & Medicaid Services (CMS) has granted a temporary New Technology Add-on Payment (NTAP) for Voraxaze(®) (glucarpidase), effective 1 October 2012. This new add-on payment means that the US government will pay up to 50% of the cost of Voraxaze(®) to hospitals in addition to the standard diagnosis-related group (DRG)...

2012-07-03 10:22:59

BEDFORD, Ohio, July 3, 2012 /PRNewswire/ -- Bedford Laboratories((TM)) today announced a nationwide voluntary hospital/user-level recall for: Product Description NDC Package Size Lot#/Expiration Date First Ship Date Last Ship Date ---...

2012-06-04 02:26:15

WEST CONSHOHOCKEN, Pa., June 4, 2012 /PRNewswire/ -- BTG International Inc., the specialist healthcare company, today announces the presentation of data on Voraxaze(®) (glucarpidase) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1-5, 2012 in Chicago, Illinois. BTG received US regulatory approval for Voraxaze(®) on 17 January 2012, and the data presented formed a key part of the Biologics License Application (BLA) submission. Clinical data on the...

2012-04-30 02:25:48

WEST CONSHOHOCKEN, Pa., April 30, 2012 /PRNewswire/ -- BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze® (glucarpidase) in the US. Voraxaze® is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Voraxaze® breaks down methotrexate into inactive metabolites which are then eliminated from the body by routes...

2010-09-08 13:46:41

Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness, according to a study in the September 8 issue of JAMA. "Pancreatic cancer is one of the major causes of cancer death globally, with a 5-year survival rate of less than 5...

2009-03-16 14:59:00

Leucovorin Calcium Augments CorePharma's Growing Product Portfolio LAKE FOREST, Ill., March 16 /PRNewswire/ -- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company CorePharma LLC ("CorePharma") has completed the acquisition of an ANDA for Leucovorin Calcium tablets. Leucovorin Calcium tablets are the generic equivalent to the Wellcovorin(R) brand previously marketed...

2008-11-07 09:00:24

Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI) announced today that the Centers for Medicare and Medicaid Services (CMS), under the Medicare Part B benefit, has assigned a unique, product-specific billing code, or J-code, for FUSILEV(TM) (levoleucovorin). FUSILEV(TM) is the only commercially available formulation comprised only of the pharmacologically active isomer of leucovorin. The J-code J06410 becomes effective on January 1, 2009, and will assist providers in obtaining reimbursement for...

2008-10-31 09:00:08

Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI) today announced that it has filed with the FDA the supplemental NDA for FUSILEV(TM) (levoleucovorin) for injection in combination with 5-FU containing regimens in advanced metastatic colorectal cancer. FUSILEV is the only commercially available formulation comprised only of the pharmacologically active isomer of leucovorin. "Ninety percent of the more than 500 million milligrams of leucovorin used in the United States is for colorectal...

2008-08-17 18:00:12

-- FUSILEV Is Now Available From Distributors And Wholesalers -- FUSILEV Was The First Proprietary Oncology Drug Approved By The FDA In 2008 Spectrum Pharmaceuticals, Inc. Russell Skibsted, SVP & Chief Business Officer 949-788-6700 x234 or Paul Arndt, Manager, Investor Relations 949-788-6700 x216 Logo: http://www.spectrumpharm.com Spectrum Pharmaceuticals, Inc., (NasdaqGM: SPPI) today launched FUSILEV(TM) (levoleucovorin) for injection. "The launch of FUSILEV...